Kessinger A, Armitage JO, Landmark J, Weisenburger D. Reconstitution of human hematopoietic function with autologous cryopreserved circulating stem cells. Exp Hematol. 1986;14:192–6.
Kessinger A, Armitage JO, Landmark JD, Smith DM, Weisenburger DD. Autologous peripheral hematopoietic stem cell transplantation restores hematopoietic function following marrow ablative therapy. 1988;71:723–7.
Abdrabou AK, Sharif FA, Fakih RE, Hashmi S, Khafaga YM, Alhayli S, et al. Outcomes of autologous stem cell transplantation for multiple myeloma in Saudi Arabia. Ann Saudi Med. 2021;41:198–205.
Niederwieser D, Baldomero H, Bazuaye N, Bupp C, Chaudhri N, Corbacioglu S, et al. One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors. Haematologica. 2022;107:1045.
Fermand J-P, Katsahian S, Divine M, Leblond V, Dreyfus F, Macro M, et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol. 2005;23:9227–33.
Philip T, Guglielmi C, Hagenbeek A, Somers R, Van Der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med. 1995;333:1540–5.
André M, Henry-Amar M, Pico J-L, Brice P, Blaise D, Kuentz M, et al. Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin’s disease induction failure: a case-control study. J Clin Oncol. 1999;17:222.
Carella AM, Bellei M, Brice P, Gisselbrecht C, Visani G, Colombat P, et al. High-dose therapy and autologous stem cell transplantation versus conventional therapy for patients with advanced Hodgkin’s lymphoma responding to front-line therapy: long-term results. Haematologica. 2009;94:146.
Gorin N. Collection, manipulation and freezing of haemopoietic stem cells. Clin Haematol. 1986;15:19–48.
Billen D. Recovery of lethally irradiat-ed mice by treatment with bone marrow cells maintained in vitro. nature1957;179:574–5.
Ahmed T, Wuest D, Ciavarella D, Ayello J, Feldman EJ, Biguzzi S, et al. Marrow storage techniques: a clinical comparison of refrigeration versus cryopreservation. Acta Haematol. 1991;85:173–8.
Sierra J, Conde E, Iriondo A, Brunet S, Marin J, de Oteiza JP, et al. Frozen vs. nonfrozen bone marrow for autologous transplantation in lymphomas: a report from the Spanish GEL/TAMO Cooperative Group. Ann Hematol. 1993;67:111–4.
Preti R, Razis E, Ciavarella D, Fan Y, Kuhns R, Cook P, et al. Clinical and laboratory comparison study of refrigerated and cryopreserved bone marrow for transplantation. Bone Marrow Transplant. 1994;13:253–60.
Hechler G, Weide R, Heymanns J, Köppler H, Havemann K. Storage of noncryopreserved periphered blood stem cells for transplantation. Ann Hematol. 1996;72:303–6.
Wannesson L, Panzarella T, Mikhael J, Keating A. Feasibility and safety of autotransplants with noncryopreserved marrow or peripheral blood stem cells: a systematic review. Ann Oncol. 2007;18:623–32.
Al-Anazi KA. Autologous hematopoietic stem cell transplantation for multiple myeloma without cryopreservation. Bone Marrow Res. 2012;2012:917361.
Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M. et al. The NewcastleOttawa Scale (NOS) for assessing the quality if nonrandomized studies in metaanalyses. Ontario, Canada. 2024. https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.
DerSimonian R, Kacker R. Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials. 2007;28:105–14.
Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135.
Freeman MF, Tukey JW. Transformations related to the angular and the square root. Ann Math Stat. 1950;21:607–11.
Barendregt JJ, Doi SA, Lee YY, Norman RE, Vos T. Meta-analysis of prevalence. J Epidemiol Community Health. 2013;67:974–8.
Lewis S, Clarke MJB. Forest plots: trying to see the wood and the trees. 2001;322:1479–80.
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. 2003;327:557–60.
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264–9.
Papadimitriou CA, Dimopoulos MA, Kouvelis V, Kostis E, Kapsimali V, Contoyannis D, et al. Non‐cryopreserved peripheral blood progenitor cells collected by a single very large‐volume leukapheresis: a simplified and effective procedure for support of high‐dose chemotherapy. J Clin Apher. 2000;15:236–41.
Ruiz-Argüelles GJ, Gómez-Rangel D, Ruiz-Delgado GJ, Ruiz-Argüelles A, Pérez-Romano B, Rivadeneyra L. Results of an autologous noncryopreserved, unmanipulated peripheral blood hematopoietic stem cell transplant program: a single-institution, 10-year experience. Acta Haematol. 2003;110:179–83.
Cuellar-Ambrosi F, Karduss U, Gomez W, Mondragon M, Velasquez-Lopera M, Calle S, editors. Hematologic reconstitution following high-dose and supralethal chemoradiotherapy using stored, noncryopreserved autologous hematopoietic stem cells. Transplantation Proc. 2004;36:1704–5.
Mabed M, Shamaa S. High-dose chemotherapy plus non-cryopreserved autologous peripheral blood stem cell transplantation rescue for patients with refractory or relapsed Hodgkin disease. Biol Blood Marrow Transpl. 2006;12:942–8.
Mabed M, Al-Kgodary T. Cyclophosphamide, etoposide and carboplatine plus non-cryopreserved autologous peripheral blood stem cell transplantation rescue for patients with refractory or relapsed non-Hodgkin’s lymphomas. Bone marrow Transplant. 2006;37:739–43.
López-Otero A, Ruiz-Delgado G, Ruiz-Argüelles G. A simplified method for stem cell autografting in multiple myeloma: a single institution experience. Bone Marrow Transplant. 2009;44:715–9.
Ramzi M, Zakerinia M, Nourani H, Dehghani M, Vojdani R, Haghighinejad H. Non‐cryopreserved hematopoietic stem cell transplantation in multiple myeloma, a single center experience. Clin Transplant. 2012;26:117–22.
Ramzi M, Mohamadian M, Vojdani R, Dehghani M, Nourani H, Zakerinia M, et al. Autologous noncryopreserved hematopoietic stem cell transplant with CEAM as a modified conditioning regimen in patients with Hodgkin lymphoma: a single-center experience with a new protocol. Exp Clin Transpl. 2012;10:163–7.
Bekadja M-A, Brahimi M, Osmani S, Arabi A, Bouhass R, Yafour N, et al. A simplified method for autologous stem cell transplantation in multiple myeloma. Hematol Oncol Stem Cell Ther. 2012;5:49–53.
Kayal S, Sharma A, Iqbal S, Tejomurtula T, Cyriac SL, Raina V. High-dose chemotherapy and autologous stem cell transplantation in multiple myeloma: a single institution experience at All India Institute of Medical Sciences, New Delhi, using non-cryopreserved peripheral blood stem cells. Clin Lymphoma Myeloma Leuk. 2014;14:140–7.
Bekadja MA, Brahimi M, Osmani S, Yafour N, Krim A, Serradj F, et al. Hematopoietic stem cell transplantation in Algeria. Hematol Oncol Stem Cell Ther. 2017;10:311–4.
Sarmiento M, Ramírez P, Parody R, Salas M, Beffermann N, Jara V, et al. Advantages of non-cryopreserved autologous hematopoietic stem cell transplantation against a cryopreserved strategy. Bone Marrow Transplant. 2018;53:960–6.
Kardduss-Urueta A, Gale RP, Gutierrez-Aguirre CH, Herrera-Rojas MA, Murrieta-Álvarez I, Perez-Fontalvo R, et al. Freezing the graft is not necessary for autotransplants for plasma cell myeloma and lymphomas. Bone Marrow Transpantl. 2018;53:457–60.
Naithani R, Dayal N, Pathak S, Rai R. Hematopoietic stem cell transplantation using non-cryopreserved peripheral blood stem cells graft is effective in multiple myeloma and lymphoma. Bone Marrow Transplant. 2018;53:1198–200.
Kulkarni U, Devasia AJ, Korula A, Fouzia N, Nisham P, Samoon YJ, et al. Use of non-cryopreserved peripheral blood stem cells is associated with adequate engraftment in patients with multiple myeloma undergoing an autologous transplant. Biol Blood Marrow Transplant. 2018;24:e31–5.
Bittencourt M, Mariano L, Moreira F, Schmidt-Filho J, Mendrone-Jr A, Rocha V. Cryopreserved versus non-cryopreserved peripheral blood stem cells for autologous transplantation after high-dose Melphalan in multiple myeloma: comparative analysis. Bone marrow Transplant. 2019;54:138–41.
Jennane S, Hasnaoui N, Mahtat E, Merimi F, Bougar S, El Maaroufi H, et al. Non-cryopreserved peripheral blood stem cells autologous transplantation in multiple myeloma: bicentric study. Transfus Clin Biol. 2020;27:152–6.
Piriyakhuntorn P, Tantiworawit A, Rattanathammethee T, Hantrakool S, Chai-Adisaksopha C, Rattarittamrong E. et al. Outcomes of non-cryopreserved versus cryopreserved peripheral blood stem cells for autologous stem cell transplantation in multiple myeloma. Ann Transplant. 2020;25:e927084-1–7.
Bekadja M-A, Boumendil A, Blaise D, Chevallier P, Peggs KS, Salles G, et al. Non-cryopreserved hematopoietic stem cells in autograft patients with lymphoma: a matched-pair analysis comparing a single center experience with the use of cryopreserved stem cells reported to the European Society for Blood and Marrow Transplantation registry. Cytotherapy. 2021;23:483–7.
Fleming K, Hubel A. Cryopreservation of hematopoietic and non-hematopoietic stem cells. Transfus Apheresis Sci. 2006;34:309–15.
Lobo F, Kessinger A, Landmark J, Smith D, Weisenburger D, Wigton R, et al. Addition of peripheral blood stem cells collected without mobilization techniques to transplanted autologous bone marrow did not hasten marrow recovery following myeloablative therapy. Bone marrow Transplant. 1991;8:389–92.
Smith R, Sweetenham J. A mononuclear cell dose of 3 x 10 (8)/kg predicts early multilineage recovery in patients with malignant lymphoma treated with carmustine, etoposide, Ara-C and melphalan (BEAM) and peripheral blood progenitor cell transplantation. Exp Hematol. 1995;23:1581–8.
Bekadja M, Talhi S, Amani K, Osmani S, Brahimi M, Mazari M, et al. Outcomes of modified-eam conditioned autologous non-cryopreserved hematopoietic sct for lymphoma. a retrospective single-centre study. Bone Marrow Transplant. 2018;53:1596–8.
Garifullin A, Voloshin S, Linnikov S, Kuzyaeva A, Balashova V, Chubukina Z. The use of non-cryopreserved and cryopreserved hematopoietic stem cells for autotransplantation in multiple myeloma. HemaSphere. 2021;5:494–5.
Lanza F, Campioni DC, Hellmann A, Milone G, Wahlin A, Walewski J, et al. Individual quality assessment of autografting by probability estimation for clinical endpoints: a prospective validation study from the European group for blood and marrow transplantation. Biol Blood Marrow Transplant. 2013;19:1670–6.
Bekadja MA, Omani S, Talhi S, Brahimi M, Yafour N, Arabi A, et al. L’autogreffe de cellules souches périphériques (CSP) non cryopréservées dans les lymphomes de Hodgkin (LH). Expérience de I’EHU 1er novembre d’Oran. Revue Algérienne d’Hématologie. 2015;10-11:40-45
